{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:47:13Z","timestamp":1747198033650,"version":"3.40.5"},"reference-count":16,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"DOI":"10.1515\/cclm-2019-0158","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T17:02:38Z","timestamp":1563987758000},"page":"e24-e26","source":"Crossref","is-referenced-by-count":0,"title":["JAK2, 46\/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential"],"prefix":"10.1515","volume":"58","author":[{"given":"Leonardo","family":"Campiotti","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery , Universit\u00e0 degli Studi dell\u2019Insubria , Varese , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Elli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery , Universit\u00e0 degli Studi dell\u2019Insubria , Varese , Italy"},{"name":"SSD Laboratorio Analisi \u2013 SMEL Specializzato in Citogenetica e Genetica Medica , ASST Sette laghi , Varese , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-7538","authenticated-orcid":false,"given":"Matteo B.","family":"Suter","sequence":"additional","affiliation":[{"name":"UO Oncologia Medica, Medical Oncology, Ospedale di Circolo e Fondazione Macchi , ASST Sette laghi , Viale Borri 57 , Varese 21100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigina","family":"Guasti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery , Universit\u00e0 degli Studi dell\u2019Insubria , Varese , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pallotti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery , Universit\u00e0 degli Studi dell\u2019Insubria , Varese , Italy"},{"name":"SSD Laboratorio Analisi \u2013 SMEL Specializzato in Citogenetica e Genetica Medica , ASST Sette laghi , Varese , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"2022031413511224078_j_cclm-2019-0158_ref_001","doi-asserted-by":"crossref","unstructured":"Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446\u20139.","DOI":"10.1038\/ng.334"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_002","doi-asserted-by":"crossref","unstructured":"Macedo LC, Santos BC, Pagliarini-e-Silva S, Pagnano KB, Rodrigues C, Quintero FC, et al. JAK2 46\/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Brazilian patients. Int J Lab Hematol 2015;37:654\u201360.","DOI":"10.1111\/ijlh.12380"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_003","doi-asserted-by":"crossref","unstructured":"Villani L, Bergamaschi G, Primignani M, Rosti V, Carolei A, Poletto V, et al. JAK2 46\/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leuk Res 2012;36:e7\u20139.","DOI":"10.1016\/j.leukres.2011.08.008"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_004","doi-asserted-by":"crossref","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290\u20133.","DOI":"10.1038\/243290a0"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_005","doi-asserted-by":"crossref","unstructured":"Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, et al. Localization of the c-AB1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983;306:239\u201342.","DOI":"10.1038\/306239a0"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_006","doi-asserted-by":"crossref","unstructured":"Martin-Cabrera P, Haferlach C, Kern W, Schnittger S, Haferlach T. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br J Haematol 2017;176:135\u20139.","DOI":"10.1111\/bjh.13932"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_007","doi-asserted-by":"crossref","unstructured":"Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 2009;33:e212\u20133.","DOI":"10.1016\/j.leukres.2009.06.011"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_008","doi-asserted-by":"crossref","unstructured":"Spolverini A, Jones AV, Hochhaus A, Pieri L, Cross NC, Vannucchi AM. The myeloproliferative neoplasm-associated JAK2 46\/1 haplotype is not overrepresented in chronic myelogenous leukemia. Ann Hematol 2011;90:365\u20136.","DOI":"10.1007\/s00277-010-1009-y"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_009","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14\u201322.","DOI":"10.1038\/sj.leu.2404955"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_010","doi-asserted-by":"crossref","unstructured":"Michiels JJ, Ten Kate F, Lam KH, Schroyens W, Berneman Z, De Raeve H. The European Clinical Molecular and Pathological (ECMP) criteria and the 2007\/2008 revisions of the World Health Organization (WHO) for the diagnosis, classification and staging of prefibrotic myeloproliferative neoplasms carrying the JAK2V617F mutation. Turk J Hematol 2014;31:136\u201342.","DOI":"10.4274\/Tjh.2013.0131"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_011","doi-asserted-by":"crossref","unstructured":"van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13:1901\u201328.","DOI":"10.1038\/sj.leu.2401592"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_012","doi-asserted-by":"crossref","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program. Leukemia 2003;17:2318\u201357.","DOI":"10.1038\/sj.leu.2403135"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_013","unstructured":"http:\/\/www.internationalgenome.org\/1000-genomes-browsers\/. Accessed on 25 Nov 2018."},{"key":"2022031413511224078_j_cclm-2019-0158_ref_014","doi-asserted-by":"crossref","unstructured":"Anelli L, Zagaria A, Specchia G, Albano F. The JAK2 GGCC (46\/1) haplotype in myeloproliferative neoplasms: causal or random? Int J Mol Sci 2018;19:1152.","DOI":"10.3390\/ijms19041152"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_015","doi-asserted-by":"crossref","unstructured":"Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 2017;77:48\u201356.","DOI":"10.1016\/j.ejca.2017.02.028"},{"key":"2022031413511224078_j_cclm-2019-0158_ref_016","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872\u201384.","DOI":"10.1182\/blood-2013-05-501569"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2020.58.issue-1\/cclm-2019-0158\/cclm-2019-0158.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0158\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T15:09:12Z","timestamp":1647270552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0158\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,8,5]]},"published-print":{"date-parts":[[2019,12,18]]}},"alternative-id":["10.1515\/cclm-2019-0158"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0158","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"type":"electronic","value":"1437-4331"},{"type":"print","value":"1434-6621"}],"subject":[],"published":{"date-parts":[[2019,7,24]]}}}